- 現金殖利率: 3.1%、總殖利率: 3.1%、5年平均現金配發率: 119.39%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 0.56 | -9.68 | 0.60 | 0.0 | 0.00 | 0 | 107.14 | 10.71 | 0.00 | 0 | 107.14 | 10.71 |
| 2022 (9) | 0.62 | 44.19 | 0.60 | 50.0 | 0.00 | 0 | 96.77 | 4.03 | 0.00 | 0 | 96.77 | 4.03 |
| 2021 (8) | 0.43 | 186.67 | 0.40 | 33.33 | 0.00 | 0 | 93.02 | -53.49 | 0.00 | 0 | 93.02 | -53.49 |
| 2020 (7) | 0.15 | -50.0 | 0.30 | 0.0 | 0.00 | 0 | 200.00 | 100.0 | 0.00 | 0 | 200.00 | 100.0 |
| 2019 (6) | 0.30 | 76.47 | 0.30 | -25.0 | 0.00 | 0 | 100.00 | -57.5 | 0.00 | 0 | 100.00 | -57.5 |
| 2018 (5) | 0.17 | -5.56 | 0.40 | 0.0 | 0.00 | 0 | 235.29 | 5.88 | 0.00 | 0 | 235.29 | 5.88 |
| 2017 (4) | 0.18 | -60.87 | 0.40 | 0.0 | 0.00 | 0 | 222.22 | 155.56 | 0.00 | 0 | 222.22 | 155.56 |
| 2016 (3) | 0.46 | -8.0 | 0.40 | -20.0 | 0.00 | 0 | 86.96 | -13.04 | 0.00 | 0 | 86.96 | -13.04 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 23Q4 (20) | 0.28 | 100.0 | 300.0 | 0.21 | 110.0 | 61.54 | 0.57 | 96.55 | -8.06 |
| 23Q3 (19) | 0.14 | 16.67 | -41.67 | 0.10 | 0.0 | 233.33 | 0.29 | 107.14 | -47.27 |
| 23Q2 (18) | 0.12 | 500.0 | -14.29 | 0.10 | 400.0 | 0 | 0.14 | 600.0 | -54.84 |
| 23Q1 (17) | 0.02 | -71.43 | -88.89 | 0.02 | -84.62 | -89.47 | 0.02 | -96.77 | -88.89 |
| 22Q4 (16) | 0.07 | -70.83 | -63.16 | 0.13 | 333.33 | -31.58 | 0.62 | 12.73 | 44.19 |
| 22Q3 (15) | 0.24 | 71.43 | 50.0 | 0.03 | 0 | 400.0 | 0.55 | 77.42 | 120.0 |
| 22Q2 (14) | 0.14 | -22.22 | 250.0 | 0.00 | -100.0 | 100.0 | 0.31 | 72.22 | 244.44 |
| 22Q1 (13) | 0.18 | -5.26 | 260.0 | 0.19 | 0.0 | 733.33 | 0.18 | -58.14 | 260.0 |
| 21Q4 (12) | 0.19 | 18.75 | -9.52 | 0.19 | 2000.0 | -5.0 | 0.43 | 72.0 | 186.67 |
| 21Q3 (11) | 0.16 | 300.0 | 128.57 | -0.01 | 50.0 | 85.71 | 0.25 | 177.78 | 516.67 |
| 21Q2 (10) | 0.04 | -20.0 | 200.0 | -0.02 | 33.33 | 75.0 | 0.09 | 80.0 | 169.23 |
| 21Q1 (9) | 0.05 | -76.19 | 155.56 | -0.03 | -115.0 | 72.73 | 0.05 | -66.67 | 155.56 |
| 20Q4 (8) | 0.21 | 200.0 | 162.5 | 0.20 | 385.71 | 900.0 | 0.15 | 350.0 | -50.0 |
| 20Q3 (7) | 0.07 | 275.0 | -50.0 | -0.07 | 12.5 | -450.0 | -0.06 | 53.85 | -127.27 |
| 20Q2 (6) | -0.04 | 55.56 | -233.33 | -0.08 | 27.27 | -188.89 | -0.13 | -44.44 | -262.5 |
| 20Q1 (5) | -0.09 | -212.5 | -280.0 | -0.11 | -650.0 | -650.0 | -0.09 | -130.0 | -280.0 |
| 19Q4 (4) | 0.08 | -42.86 | 0.0 | 0.02 | 0.0 | 0.0 | 0.30 | 36.36 | 0.0 |
| 19Q3 (3) | 0.14 | 366.67 | 0.0 | 0.02 | -77.78 | 0.0 | 0.22 | 175.0 | 0.0 |
| 19Q2 (2) | 0.03 | -40.0 | 0.0 | 0.09 | 350.0 | 0.0 | 0.08 | 60.0 | 0.0 |
| 19Q1 (1) | 0.05 | 0.0 | 0.0 | 0.02 | 0.0 | 0.0 | 0.05 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/3 | 6.57 | 3.88 | 7.35 | 20.4 | 10.61 | 20.4 | N/A | - | ||
| 2024/2 | 6.33 | -15.72 | 10.59 | 13.83 | 12.23 | 22.22 | N/A | - | ||
| 2024/1 | 7.51 | -10.53 | 13.66 | 7.51 | 13.66 | 22.45 | N/A | - | ||
| 2023/12 | 8.39 | 28.01 | 21.65 | 79.89 | -10.5 | 21.98 | 0.67 | - | ||
| 2023/11 | 6.55 | -6.79 | 5.29 | 71.5 | -13.2 | 20.17 | 0.73 | - | ||
| 2023/10 | 7.03 | 6.83 | 8.73 | 64.95 | -14.71 | 20.44 | 0.72 | - | ||
| 2023/9 | 6.58 | -3.52 | -12.28 | 57.92 | -16.88 | 20.02 | 0.71 | - | ||
| 2023/8 | 6.82 | 3.07 | -9.61 | 51.34 | -17.44 | 20.85 | 0.68 | - | ||
| 2023/7 | 6.62 | -10.66 | -7.17 | 44.51 | -18.52 | 20.38 | 0.7 | - | ||
| 2023/6 | 7.41 | 16.62 | -5.38 | 37.89 | -20.22 | 19.45 | 0.61 | - | ||
| 2023/5 | 6.35 | 11.76 | -50.82 | 30.48 | -23.15 | 18.16 | 0.66 | 因子公司杏昌生技去年同期有新增快篩試劑銷售本年度因疫情趨緩銷售減少 | ||
| 2023/4 | 5.68 | -7.13 | -4.67 | 24.13 | -9.79 | 17.53 | 0.68 | - | ||
| 2023/3 | 6.12 | 7.01 | -15.03 | 18.45 | -11.27 | 18.45 | 0.7 | - | ||
| 2023/2 | 5.72 | -13.38 | 6.95 | 12.32 | -9.27 | 19.22 | 0.67 | - | ||
| 2023/1 | 6.6 | -4.24 | -19.81 | 6.6 | -19.81 | 19.73 | 0.65 | - | ||
| 2022/12 | 6.9 | 10.79 | -14.11 | 89.28 | 8.55 | 19.59 | 0.68 | - | ||
| 2022/11 | 6.22 | -3.74 | -6.51 | 82.38 | 11.01 | 20.2 | 0.66 | - | ||
| 2022/10 | 6.47 | -13.81 | -17.23 | 76.15 | 12.73 | 21.52 | 0.62 | - | ||
| 2022/9 | 7.5 | -0.58 | -3.11 | 69.69 | 16.65 | 22.18 | 0.69 | - | ||
| 2022/8 | 7.55 | 5.85 | 0.3 | 62.18 | 19.6 | 22.51 | 0.68 | - | ||
| 2022/7 | 7.13 | -8.94 | 19.04 | 54.63 | 22.87 | 27.88 | 0.55 | - | ||
| 2022/6 | 7.83 | -39.38 | 10.7 | 47.5 | 23.46 | 26.72 | 0.52 | - | ||
| 2022/5 | 12.92 | 116.65 | 122.0 | 39.67 | 26.33 | 26.09 | 0.53 | 合併子公司杏昌生技業務增加 | ||
| 2022/4 | 5.96 | -17.22 | -14.0 | 26.75 | 4.57 | 18.52 | 0.75 | - | ||
| 2022/3 | 7.2 | 34.71 | 5.36 | 20.79 | 11.48 | 20.79 | 0.6 | - | ||
| 2022/2 | 5.35 | -35.06 | -6.59 | 13.58 | 15.03 | 21.61 | 0.58 | - | ||
| 2022/1 | 8.24 | 2.55 | 35.39 | 8.24 | 35.39 | 22.92 | 0.55 | - | ||
| 2021/12 | 8.03 | 20.59 | 22.38 | 82.24 | 24.88 | 22.5 | 0.64 | - | ||
| 2021/11 | 6.66 | -14.77 | 20.58 | 74.21 | 25.16 | 22.22 | 0.65 | 貿易出貨成長 | ||
| 2021/10 | 7.81 | 0.88 | 63.63 | 67.55 | 25.63 | 23.08 | 0.62 | 貿易營收成長 | ||
| 2021/9 | 7.75 | 2.91 | 35.93 | 59.74 | 21.93 | 21.26 | 0.62 | - | ||
| 2021/8 | 7.53 | 25.63 | 26.54 | 51.99 | 20.08 | 20.59 | 0.64 | 貿易出貨成長 | ||
| 2021/7 | 5.99 | -15.32 | 6.39 | 44.46 | 19.06 | 18.88 | 0.7 | - | ||
| 2021/6 | 7.07 | 21.55 | 15.45 | 38.48 | 21.3 | 19.83 | 0.6 | - | ||
| 2021/5 | 5.82 | -16.08 | 11.16 | 31.4 | 22.71 | 19.59 | 0.61 | - | ||
| 2021/4 | 6.93 | 1.41 | 37.67 | 25.58 | 25.68 | 19.5 | 0.61 | - | ||
| 2021/3 | 6.84 | 19.42 | 38.55 | 18.65 | 21.73 | 18.65 | 0.63 | 109年受疫情影響偏低 | ||
| 2021/2 | 5.73 | -5.86 | 28.89 | 11.81 | 13.74 | 18.37 | 0.64 | 109年2月因疫情影響，致營收明顯偏低。 | ||
| 2021/1 | 6.08 | -7.29 | 2.41 | 6.08 | 2.41 | 18.17 | 0.64 | - | ||
| 2020/12 | 6.56 | 18.81 | -9.48 | 65.85 | -8.87 | 16.86 | 0.64 | - | ||
| 2020/11 | 5.52 | 15.64 | 4.06 | 59.29 | -8.8 | 15.99 | 0.67 | - | ||
| 2020/10 | 4.77 | -16.19 | -10.35 | 53.77 | -9.95 | 16.42 | 0.66 | - | ||
| 2020/9 | 5.7 | -4.19 | -5.57 | 48.99 | -9.91 | 17.28 | 0.61 | - | ||
| 2020/8 | 5.95 | 5.63 | -9.26 | 43.29 | -10.45 | 17.7 | 0.6 | - | ||
| 2020/7 | 5.63 | -8.11 | -10.74 | 37.35 | -10.64 | 16.99 | 0.62 | - | ||
| 2020/6 | 6.13 | 17.03 | -2.75 | 31.72 | -10.62 | 16.4 | 0.58 | - | ||
| 2020/5 | 5.24 | 3.93 | -4.23 | 25.59 | -12.32 | 15.21 | 0.62 | - | ||
| 2020/4 | 5.04 | 2.06 | -20.4 | 20.35 | -14.18 | 14.41 | 0.65 | - | ||
| 2020/3 | 4.94 | 11.09 | -14.81 | 15.32 | -11.92 | 15.32 | 0.64 | - | ||
| 2020/2 | 4.44 | -25.19 | -0.91 | 10.38 | -10.47 | 17.63 | 0.55 | - | ||
| 2020/1 | 5.94 | -18.06 | -14.49 | 5.94 | -14.49 | 18.49 | 0.53 | - | ||
| 2019/12 | 7.25 | 36.59 | 14.83 | 72.26 | 4.39 | 17.88 | 0.56 | - | ||
| 2019/11 | 5.31 | -0.37 | -4.09 | 65.02 | 3.34 | 16.67 | 0.61 | - | ||
| 2019/10 | 5.33 | -11.72 | -0.44 | 59.71 | 4.06 | 17.92 | 0.56 | - | ||
| 2019/9 | 6.03 | -7.94 | -4.41 | 54.38 | 4.52 | 18.9 | 0.52 | - | ||
| 2019/8 | 6.55 | 3.91 | 4.86 | 48.35 | 5.76 | 19.16 | 0.51 | - | ||
| 2019/7 | 6.31 | 0.1 | 11.37 | 41.79 | 5.9 | 18.08 | 0.54 | - | ||
| 2019/6 | 6.3 | 15.26 | 6.3 | 35.49 | 4.98 | 18.1 | 0.54 | - | ||
| 2019/5 | 5.47 | -13.62 | -4.58 | 29.19 | 4.7 | 0.0 | N/A | - | ||
| 2019/4 | 6.33 | 9.23 | 14.39 | 23.72 | 7.1 | 0.0 | N/A | - |
